Latest Period
Q1 2026
Security Snapshot
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) Institutional Ownership
CUSIP: 98422T100
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
1
Shares (Excl. Options)
650,389
Price
$8.41
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- XLO on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 650,389
- Total 13F value
- $5,469,771
- Portfolio coverage rank
- 0%
- Share change
- -37,821,734
- Value change
- -$89,907,489
- Number of holders
- 1
- Shares outstanding
- 6,426,426
- SEC-reported price per share
- $8.41
- Insider filing price
- $8.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 98422T100.
- 1 institution reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 37 to 1 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $25,433,377 to $5,469,771.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q1 2026.
Security key
98422T100
Latest holder period
Q1 2026
13F holders
1
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
XLO full holder history
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Xilio Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98422T100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
XLO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 20% | 0% | $9,581,667 | +$2,576,464 | 14,517,678 | +37% | GILEAD SCIENCES, INC. | 31 Dec 2025 |
| STEMPOINT CAPITAL LP | 8.4% | +17% | $3,979,818 | +$1,339,818 | 6,030,028 | +51% | StemPoint Capital LP | 31 Dec 2025 |
| Coastlands Capital LP | 10% | $3,742,248 | 5,346,069 | Coastlands Capital LP | 04 Dec 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 6.7% | -32% | $3,086,472 | -$2,286,600 | 4,676,472 | -43% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| AbbVie Inc. | 9% | $3,304,348 | 4,347,826 | AbbVie Inc. | 11 Feb 2025 | |||
| Sirenia Capital Management LP | 9.9% | $9,611,469 | 1,142,862 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Bain Capital Life Sciences Fund II, L.P. | 10% | +17% | $5,584,417 | -$47,060,014 | 664,021 | -89% | BCLS II Equity Opportunities, LP | 31 Mar 2026 |
| ORBIMED ADVISORS LLC | 10% | $5,399,220 | 642,000 | ORBIMED ADVISORS LLC | 31 Mar 2026 |
As of 31 Mar 2026, 1 institutional investors reported holding 650,389 shares of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO). This represents 10% of the company’s total 6,426,426 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
10%
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 650,389 | $5,469,771 | -$89,907,489 | $8.41 | 1 |
| 2025 Q4 | 39,727,815 | $25,433,377 | +$11,324,174 | $0.64 | 37 |
| 2025 Q3 | 22,051,916 | $18,613,906 | -$1,227,318 | $0.84 | 36 |
| 2025 Q2 | 23,795,263 | $16,179,092 | +$854,217 | $0.68 | 35 |
| 2025 Q1 | 22,528,206 | $16,318,555 | -$3,181,066 | $0.72 | 35 |
| 2024 Q4 | 25,814,355 | $24,660,128 | -$144,644 | $0.96 | 34 |
| 2024 Q3 | 15,911,945 | $12,534,583 | +$1,128,156 | $0.79 | 32 |
| 2024 Q2 | 14,508,823 | $13,746,216 | +$1,785,264 | $0.95 | 31 |
| 2024 Q1 | 12,460,895 | $13,460,257 | -$2,676,053 | $1.08 | 30 |
| 2023 Q4 | 16,426,281 | $9,034,716 | -$1,543,598 | $0.55 | 33 |
| 2023 Q3 | 15,860,160 | $33,465,952 | -$314,935 | $2.11 | 30 |
| 2023 Q2 | 16,002,286 | $41,925,598 | -$192,245 | $2.62 | 32 |
| 2023 Q1 | 16,072,057 | $50,979,505 | +$461,644 | $3.17 | 32 |
| 2022 Q4 | 15,926,513 | $42,841,966 | -$709,927 | $2.69 | 28 |
| 2022 Q3 | 16,606,568 | $48,328,000 | -$3,750,524 | $2.91 | 28 |
| 2022 Q2 | 17,880,380 | $52,211,910 | -$3,647,986 | $2.92 | 29 |
| 2022 Q1 | 18,775,939 | $132,746,000 | -$2,569,332 | $7.07 | 41 |
| 2021 Q4 | 18,324,586 | $269,421,063 | +$225,248,000 | $16.00 | 41 |